Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04137107
This phase II/III trial studies the best dose of duloxetine and how well it works in
preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with
oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount
of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in
patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent
peripheral neuropathy.
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Ellen M. Lavoie Smith, PhD, Richard L. Deming, Elie G. Dib, Dennis Hsu

See list of participating sites